Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025)
Inhibrx Biosciences' (INBX) quarterly Cash from Investing Activities came in at -$7000.0 in Q3 2025, up 97.17% year-on-year from -$3550.3 in Q3 2024, and up 66.67% on a QoQ basis from -$21000.0 in Q1 2025.
Inhibrx Biosciences (INBX) Cash from Investing Activities (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Cash from Investing Activities data on file, last reported at -$7000.0 in Q3 2025.
- On a quarterly basis, Cash from Investing Activities rose 97.17% year-over-year to -$7000.0 in Q3 2025; TTM through Dec 2025 was -$28000.0, a 98.92% increase from a year earlier, with the FY2025 full-year figure at -$28000.0, up 98.92% from the prior year.
- Cash from Investing Activities for Q3 2025 stood at -$7000.0, up from -$21000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for INBX reached as high as -$7000.0 in Q3 2025 and fell as low as -$3.4 million in Q4 2023.
- Historically, Cash from Investing Activities has averaged -$859750.0 across 3 years, with a median of -$529000.0 in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 99.54% in 2024 and fell as far as 69.54% in 2024.
- Year by year, Cash from Investing Activities stood at -$3.4 million in 2023, then soared by 99.54% to -$16000.0 in 2024, then soared by 56.25% to -$7000.0 in 2025.
- Per Business Quant data, the three most recent Cash from Investing Activities figures were -$7000.0 in Q3 2025, -$21000.0 in Q1 2025, and -$16000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 470.97 Bn | 466.18 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.05 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.43 Bn | 34.42 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Inhibrx Biosciences | 1.30 Bn | 1.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -7,000.00 |
| Sep 30, 2025 | -7,000.00 |
| Mar 31, 2025 | -21,000.00 |
| Mar 31, 2025 | -21,000.00 |
| Dec 31, 2024 | -16,000.00 |
| Dec 31, 2024 | -16,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Sep 30, 2024 | -247,000.00 |
| Jun 30, 2024 | -1.22 Mn |
| Jun 30, 2024 | -1.22 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Mar 31, 2024 | -1.12 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Dec 31, 2023 | -3.44 Mn |
| Sep 30, 2023 | -811,000.00 |
| Sep 30, 2023 | -811,000.00 |